Galapagos’ innovative decentralized manufacturing approach streamlines CAR T-cell production, reducing costs associated with traditional manufacturing sites. These decentralized manufacturing units (DMUs) have been established in Europe and are expanding to the United States. The Boston-based DMU is already producing CAR T-cells for a Phase 2 study targeting various B-cell malignancies. By decentralizing manufacturing, Galapagos is accelerating the delivery of CAR T-cell therapies, making them more accessible and cost-effective for patients in need.
This shift towards decentralized manufacturing not only enhances production efficiency but also paves the way for broader adoption of CAR T-cell therapies. With multiple DMUs in operation and more on the horizon, the scalability and flexibility of this approach offer promising prospects for advancing cell manufacturing capabilities. As Galapagos continues to optimize its decentralized model, the future of CAR T-cell therapy looks brighter than ever, poised to revolutionize the treatment landscape for cancer patients.
Read more about this — usatoday.com
